NCT05634018

Brief Summary

Identification of the regression model between the strength properties of tissue and its ultrasonic spectral characteristics.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2023

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 1, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2023

Completed
Last Updated

December 14, 2022

Status Verified

November 1, 2022

Enrollment Period

29 days

First QC Date

November 21, 2022

Last Update Submit

December 13, 2022

Conditions

Keywords

aneurysm wall strengthspeckle trackingshear yield strength

Outcome Measures

Primary Outcomes (1)

  • Calculate the relationship between the strength properties of the tissue and its ultrasonic spectral characteristics

    Identification of the regression relationship between the elasto-elastic and strength properties of the tissue and its ultrasonic characteristics will make it possible to determine the most significant diagnostic ultrasonic criteria for aortic wall deformation, which determine the increased risk of its rupture and thromboembolic complications in a particular patient.

    1 year

Secondary Outcomes (3)

  • Measurement of elastic-elastic properties of the aortic wall using ultrasonic speckle tracking

    at least one day prior to surgery

  • Measurement of the strength properties of the aneurysm wall in uniaxial tension in vitro

    1 month

  • Measure linearity limits as well as shear yield strength in vitro

    1 month

Interventions

Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively. In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample. The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used.

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Male and female patients aged 45 to 75 with a diagnosed aneurysmal dilatation of the abdominal aorta requiring its surgical correction, recruited in accordance with the inclusion/exclusion criteria

You may qualify if:

  • Patients with an aneurysmal expansion of the abdominal aorta who are indicated for surgery.
  • Patients who consented to participate in this study

You may not qualify if:

  • Chronic heart failure III-IV functional class according to the NYHA classification;
  • Chronic decompensated "pulmonary" heart;
  • Severe hepatic or renal insufficiency (bilirubin \> 35 mmol / l, glomerular filtration rate \< 60 ml / min);
  • Polyvalent drug allergy;
  • Malignant oncological diseases in the terminal stage with a predicted lifespan of up to 6 months;
  • Acute violation of cerebral circulation;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Alexander A Gostev

Novosibirsk, Novosibirskaya Obl, 630005, Russia

Location

Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology

Novosibirsk, 630055, Russia

Location

E. Meshalkin National Medical Research Center

Novosibirsk, Russia

Location

Central Study Contacts

Andrey A Karpenko, PhD

CONTACT

Alexandr A Gostev, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Month
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2022

First Posted

December 1, 2022

Study Start

January 1, 2023

Primary Completion

January 30, 2023

Study Completion

April 30, 2023

Last Updated

December 14, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will share

Access to data after first publication at the request of researchers

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Access to data after first publication at the request of researchers
Access Criteria
on personal request

Locations